- Home
- XPEL vs KALV Comparison
XPEL vs KALV Comparison
Compare XPEL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- KALV
- Stock Information
- Founded
- XPEL 1999
- KALV N/A
- Country
- XPEL United States
- KALV United States
- Employees
- XPEL N/A
- KALV N/A
- Industry
- XPEL Industrial Specialties
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- KALV Health Care
- Exchange
- XPEL Nasdaq
- KALV Nasdaq
- Market Cap
- XPEL 984.3M
- KALV 796.4M
- IPO Year
- XPEL N/A
- KALV N/A
- Fundamental
- Price
- XPEL $34.03
- KALV $10.97
- Analyst Decision
- XPEL
- KALV Strong Buy
- Analyst Count
- XPEL 0
- KALV 8
- Target Price
- XPEL N/A
- KALV $26.43
- AVG Volume (30 Days)
- XPEL 289.6K
- KALV 1.5M
- Earning Date
- XPEL 11-06-2025
- KALV 09-11-2025
- Dividend Yield
- XPEL N/A
- KALV N/A
- EPS Growth
- XPEL 2.75
- KALV N/A
- EPS
- XPEL 1.76
- KALV N/A
- Revenue
- XPEL $448,897,000.00
- KALV $1,426,000.00
- Revenue This Year
- XPEL $12.54
- KALV N/A
- Revenue Next Year
- XPEL $10.52
- KALV $213.43
- P/E Ratio
- XPEL $19.22
- KALV N/A
- Revenue Growth
- XPEL 9.96
- KALV N/A
- 52 Week Low
- XPEL $24.25
- KALV $7.30
- 52 Week High
- XPEL $47.23
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- XPEL 47.81
- KALV 32.68
- Support Level
- XPEL $31.87
- KALV $11.93
- Resistance Level
- XPEL $35.02
- KALV $12.04
- Average True Range (ATR)
- XPEL 1.11
- KALV 0.56
- MACD
- XPEL 0.17
- KALV -0.21
- Stochastic Oscillator
- XPEL 66.86
- KALV 10.10
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.